These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34108184)

  • 21. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
    Casadei-Gardini A; Scartozzi M; Tada T; Yoo C; Shimose S; Masi G; Lonardi S; Frassineti LG; Nicola S; Piscaglia F; Kumada T; Kim HD; Koga H; Vivaldi C; Soldà C; Hiraoka A; Bang Y; Atsukawa M; Torimura T; Tsuj K; Itobayashi E; Toyoda H; Fukunishi S; Rimassa L; Rimini M; Cascinu S; Cucchetti A
    Liver Int; 2021 Jun; 41(6):1389-1397. PubMed ID: 33547848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
    Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
    Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
    He K; Yang Z; Liu X; Yang Y; Song W; Wang S; Chen Y
    Curr Oncol; 2022 Dec; 30(1):476-491. PubMed ID: 36661687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
    Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
    World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 26. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
    Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
    Tahara M; Schlumberger M; Elisei R; Habra MA; Kiyota N; Paschke R; Dutcus CE; Hihara T; McGrath S; Matijevic M; Kadowaki T; Funahashi Y; Sherman SI
    Eur J Cancer; 2017 Apr; 75():213-221. PubMed ID: 28237867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma.
    Baxter MA; Glen H; Evans TR
    Future Oncol; 2018 Aug; 14(20):2021-2029. PubMed ID: 29783903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
    Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
    Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
    Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
    Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
    BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
    Park MK; Lee YB; Moon H; Choi NR; Kim MA; Jang H; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
    Dig Dis Sci; 2022 Oct; 67(10):4939-4949. PubMed ID: 35048224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
    Hsu PY; Cheng TS; Chuang SC; Chang WT; Liang PC; Hsu CT; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Huang JF; Chuang WL; Huang CF; Yu ML
    Cancer Med; 2022 Jan; 11(1):104-116. PubMed ID: 34786871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma.
    Sasaki R; Fukushima M; Haraguchi M; Honda T; Miuma S; Miyaaki H; Nakao K
    Medicine (Baltimore); 2022 May; 101(19):e29289. PubMed ID: 35583540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
    Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
    PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
    Kobayashi M; Kudo M; Izumi N; Kaneko S; Azuma M; Copher R; Meier G; Pan J; Ishii M; Ikeda S
    J Gastroenterol; 2019 Jun; 54(6):558-570. PubMed ID: 30788569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
    Ikeda M; Kobayashi M; Tahara M; Kaneko S
    Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenvatinib mesylate to treat hepatocellular carcinoma.
    Ielasi L; Tovoli F; Piscaglia F
    Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Varying Impact of Lenvatinib or Sorafenib Therapy on Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma.
    Yamauchi Y; Saeki I; Fujisawa K; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Sasaki R; Nishimura T; Tanabe N; Hisanaga T; Matsumoto T; Ishikawa T; Yamasaki T; Takami T
    Oncology; 2024; 102(9):794-799. PubMed ID: 38286117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.